Country: Canada
Language: English
Source: Health Canada
ALIROCUMAB
SANOFI-AVENTIS CANADA INC
C10AX14
ALIROCUMAB
75MG
SOLUTION
ALIROCUMAB 75MG
SUBCUTANEOUS
1ML
Prescription
PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9) INHIBITORS
Active ingredient group (AIG) number: 0158030001; AHFS:
APPROVED
2016-04-11
_Product Monograph – Praluent _ _ _ _Page 1 of 57_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR PRALUENT ® alirocumab injection solution for subcutaneous injection, 75 mg/mL and 150 mg/mL, subcutaneous Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor produced by recombinant DNA technology in Chinese Hamster Ovary cell suspension culture ATC Code: C10AX14 Sanofi-aventis Canada Inc. 2905 Place Louis-R-Renaud Laval, Quebec H7V0A3 Date of Initial Approval: April 11, 2016 Date of Revision: February 17, 2023 Submission Control No: 261559 _ _ _Product Monograph – Praluent _ _ _ _Page 2 of 57_ RECENT MAJOR LABEL CHANGES 1 INDICATIONS, 1.1 Pediatrics 01/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES..............................................................................................2 TABLE OF CONTENTS ................................................................................................................2 PART I: HEALTH PROFESSIONAL INFORMATION .......................................................................4 1 INDICATIONS ................................................................................................................4 1.1 Pediatrics ............................................................................................................4 1.2 Geriatrics .............................................................................................................4 2 CONTRAINDICATIONS ...................................................................................................4 4 DOSAGE AND ADMINISTRATION...................................................................................5 4.2 Recommended Dose and Dosage Adjustment.......................................................5 4.4 Administration .....................................................................................................5 4.5 Missed Dose .......................... Read the complete document